1. Home
  2. ARCT vs MDWD Comparison

ARCT vs MDWD Comparison

Compare ARCT & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

SELL

Current Price

$12.13

Market Cap

369.5M

Sector

Health Care

ML Signal

SELL

Logo MediWound Ltd.

MDWD

MediWound Ltd.

SELL

Current Price

$12.32

Market Cap

161.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ARCT
MDWD
Founded
2013
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
369.5M
161.9M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
ARCT
MDWD
Price
$12.13
$12.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
6
Target Price
$23.80
★ $30.67
AVG Volume (30 Days)
★ 756.6K
66.4K
Earning Date
11-09-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 20.00
N/A
EPS
N/A
★ N/A
Revenue
★ $82,031,000.00
N/A
Revenue This Year
N/A
$39.60
Revenue Next Year
$64.21
$34.34
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.50
$12.35
52 Week High
$24.14
$20.03

Technical Indicators

Market Signals
Indicator
ARCT
MDWD
Relative Strength Index (RSI) 42.66 32.53
Support Level $6.53 N/A
Resistance Level $17.85 $14.06
Average True Range (ATR) 1.11 0.42
MACD -0.31 -0.15
Stochastic Oscillator 8.31 4.62

Price Performance

Historical Comparison
ARCT
MDWD

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: